These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 14626298)

  • 1. Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesions.
    Daldrup-Link HE; Kaiser A; Helbich T; Werner M; Bjørnerud A; Link TM; Rummeny EJ
    Acad Radiol; 2003 Nov; 10(11):1237-46. PubMed ID: 14626298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial.
    Daldrup-Link HE; Rydland J; Helbich TH; Bjørnerud A; Turetschek K; Kvistad KA; Kaindl E; Link TM; Staudacher K; Shames D; Brasch RC; Haraldseth O; Rummeny EJ
    Radiology; 2003 Dec; 229(3):885-92. PubMed ID: 14576446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between gadopentetate and feruglose (Clariscan)-enhanced MR-mammography: preliminary clinical experience.
    Daldrup-Link HE; Kaiser A; Link TM; Settles M; Helbich T; Werner M; Roberts TP; Rummeny EJ
    Acad Radiol; 2002 Aug; 9 Suppl 2():S343-7. PubMed ID: 12188270
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
    Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R
    Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging.
    Lutz AM; Willmann JK; Goepfert K; Marincek B; Weishaupt D
    Radiology; 2005 Nov; 237(2):520-8. PubMed ID: 16192317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging.
    Tang Y; Yamashita Y; Arakawa A; Namimoto T; Mitsuzaki K; Abe Y; Katahira K; Takahashi M
    AJR Am J Roentgenol; 1999 Jun; 172(6):1547-54. PubMed ID: 10350287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superparamagnetic iron oxide--enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions.
    Vogl TJ; Hammerstingl R; Schwarz W; Mack MG; Müller PK; Pegios W; Keck H; Eibl-Eibesfeldt A; Hoelzl J; Woessmer B; Bergman C; Felix R
    Radiology; 1996 Mar; 198(3):881-7. PubMed ID: 8628887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadopentetate dimeglumine versus ultrasmall superparamagnetic iron oxide for dynamic contrast-enhanced MR imaging of tumor angiogenesis in human colon carcinoma in mice.
    de Lussanet QG; Backes WH; Griffioen AW; van Engelshoven JM; Beets-Tan RG
    Radiology; 2003 Nov; 229(2):429-38. PubMed ID: 14595147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine.
    Pediconi F; Catalano C; Occhiato R; Venditti F; Fraioli F; Napoli A; Kirchin MA; Passariello R
    Radiology; 2005 Oct; 237(1):45-56. PubMed ID: 16126926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign and malignant breast lesions: efficacy of real time contrast-enhanced ultrasound vs. magnetic resonance imaging.
    Ricci P; Cantisani V; Ballesio L; Pagliara E; Sallusti E; Drudi FM; Trippa F; Calascibetta F; Erturk SM; Modesti M; Passariello R
    Ultraschall Med; 2007 Feb; 28(1):57-62. PubMed ID: 17304413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of spontaneous canine breast tumors using dynamic magnetic resonance imaging with 24-Gadolinium-DTPA-cascade-polymer, a new blood-pool agent. Preliminary experience.
    Adam G; Mühler A; Spüntrup E; Neuerburg JM; Kilbinger M; Bauer H; Fücezi L; Küpper W; Günther RW
    Invest Radiol; 1996 May; 31(5):267-74. PubMed ID: 8724124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-phase dynamic breast magnetic resonance imaging with two-way subtraction.
    Choi N; Han BK; Choe YH; Kim HS
    J Comput Assist Tomogr; 2005; 29(6):834-41. PubMed ID: 16272861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast-enhanced magnetic resonance imaging of the breast combined with pharmacokinetic analysis of gadolinium-DTPA uptake in the diagnosis of local recurrence of early stage breast carcinoma.
    Mussurakis S; Buckley DL; Bowsley SJ; Carleton PJ; Fox JN; Turnbull LW; Horsman A
    Invest Radiol; 1995 Nov; 30(11):650-62. PubMed ID: 8557506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine.
    Pediconi F; Catalano C; Padula S; Roselli A; Dominelli V; Cagioli S; Kirchin MA; Pirovano G; Passariello R
    AJR Am J Roentgenol; 2008 Nov; 191(5):1339-46. PubMed ID: 18941066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging.
    Kuhl CK; Bieling H; Gieseke J; Ebel T; Mielcarek P; Far F; Folkers P; Elevelt A; Schild HH
    Radiology; 1997 Jan; 202(1):87-95. PubMed ID: 8988196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Differential diagnosis of focal liver lesions with MRI using the superparamagnetic contrast medium endorem].
    Vogl TJ; Hammerstingl R; Keck H; Felix R
    Radiologe; 1995 Nov; 35(11 Suppl 2):S258-66. PubMed ID: 8588032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography.
    Gribbestad IS; Nilsen G; Fjøsne HE; Kvinnsland S; Haugen OA; Rinck PA
    J Magn Reson Imaging; 1994; 4(3):477-80. PubMed ID: 8061451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging.
    Boehm-Sturm P; Haeckel A; Hauptmann R; Mueller S; Kuhl CK; Schellenberger EA
    Radiology; 2018 Feb; 286(2):537-546. PubMed ID: 28880786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging.
    Lee JM; Kim CS; Youk JH; Lee MS
    Korean J Radiol; 2003; 4(1):9-18. PubMed ID: 12679629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.